Menzel Garry E has filed 5 insider transactions across 3 companies since June 2024.
Most recent transaction: a grant/award of 30550 shares of Black Diamond Therapeutics, Inc. ($BDTX) on June 12, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 12, 2025 | Black Diamond Therapeutics, Inc. | $BDTX | Menzel Garry E | Not found | A | Stock Option (Right to Buy) | 30550 | $0.00 | 30,550.0000 | 55,028,371 | 9999.99% | 0.06% |
| June 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Menzel Garry E | Not found | A | Director Stock Option (Right to Buy) | 29747 | $0.00 | 29,747.0000 | 54,008,883 | 9999.99% | 0.06% |
| July 1, 2024 | Adaptimmune Therapeutics PLC | $ADAPY | Menzel Garry E | Director | A | Option to purchase Ordinary Shares | 1121604 | $0.00 | 1,121,604.0000 | 1,559,183,774 | 9999.99% | 0.07% |
| June 5, 2024 | Stoke Therapeutics, Inc. | $STOK | Menzel Garry E | Not found | A | Director Stock Option (Right to Buy) | 7639 | $0.00 | 7,639.0000 | 43,994,862 | 9999.99% | 0.02% |
| June 6, 2024 | Black Diamond Therapeutics, Inc. | $BDTX | Menzel Garry E | Not found | A | Stock Option (Right to Buy) | 30550 | $0.00 | 30,550.0000 | 43,954,649 | 9999.99% | 0.07% |